Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions

Noninvasive ventilation in severe stable COPD: is it effective, and if so, in what way?

M. L. Duiverman, F. M. Struik, P. J. Wijkstra
European Respiratory Journal 2008 31: 1136-1137; DOI: 10.1183/09031936.00168207
M. L. Duiverman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
F. M. Struik
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P. J. Wijkstra
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

To the Editors:

We read with interest the systematic review of Kolodziej et al. 1 about noninvasive positive-pressure ventilation (NPPV) in severe stable chronic obstructive pulmonary disease (COPD). First of all, we would like to compliment the authors on their excellent review. It is extremely important that good-quality reviews are published in the field of NPPV in severe stable COPD. The development of new therapeutic options in these patients is increasingly being recognised as urgently needed 2.

However, we would like to comment on the conclusions Kolodziej et al. 1 draw in their review. They conclude that bilevel NPPV used in a select proportion of patients with severe stable COPD can improve gas exchange, exercise tolerance, dyspnoea, work of breathing, frequency of hospitalisation, health-related quality of life and functional status. Following this, they suggest an adjunctive role for the use of bilevel NPPV in the management of chronic respiratory failure due to COPD.

The first remark we would like to make is that their conclusions were based mostly on nonrandomised controlled trails (RCTs). Combined analysis of the results of the RCTs did not show the effect on arterial blood gases, exercise tolerance, work of breathing or hospitalisations. Evidence of an improved health-related quality of life was derived from only two studies 3, 4. Furthermore, in the study by Garrod et al. 4, the NPPV group had very low baseline Chronic Respiratory Questionnaire scores, which may have influenced their positive outcome.

Secondly, Kolodziej et al. 1 pooled studies that differed in length, control intervention and type of ventilation (daytime and nocturnal). They assessed their data on heterogeneity in study quality, patients, interventions and measurement of outcomes, and they showed that heterogeneity was evident in many parameters. This prohibits strong conclusions that NPPV is as effective in severe stable COPD.

In our opinion, in the review by Kolodziej et al. 1, there was limited discussion about the importance of achieving effective ventilation. It is suggested that with higher hours of ventilatory use, greater reduction in hypercapnia can be achieved. While this might be true for nocturnal ventilation, with daytime ventilation, considerable effects might be achieved with a reduction in hours of NPPV use. Of the RCTs included, a significant reduction in hypercapnia during spontaneous breathing of room air was shown only in the study by Díaz et al. 5. This study, and the more recent study of the same group 6, showed that considerable effects can be achieved with 3 h of NPPV during the daytime. During the night, increased upper airway resistance, decreased respiratory drive and less supervision might lead to delivery of a reduced volume to the patient. Therefore, correct monitoring of whether or not effective ventilation is achieved is very important, especially during the night. Kolodziej et al. 1 address this issue of more dynamic monitoring of effectiveness of NPPV. However, they imply that dynamic monitoring by transcutaneous measurements is preferable to arterial blood gases alone. Transcutaneous measurement of carbon dioxide with current techniques tends to drift overnight 7. In our opinion, measuring multiple arterial blood gas samples during NPPV is the gold standard. Unfortunately, until now, no RCT has monitored the effectiveness of their intervention in this way.

Our second remark relates to the importance of using high inspiratory pressures. Even higher pressures than used in most RCTs might be necessary to achieve normocapnia 8, although no clear evidence exists on exactly how high pressures should be.

Finally, we would like to comment on the selection of appropriate patients. Patients with very severe COPD seem to benefit most. Kolodziej et al. 1 emphasise that patients with severe hyperinflation may benefit most. However, too little evidence currently exists to make a clear statement about whether patients should be selected on the basis of the severity of chronic respiratory failure, hyperinflation or the height of the work of breathing.

To conclude, while the review of Kolodziej et al. 1 is timely and a major contribution, we feel the strength of the conclusions is overstated. With this review in hand, some of the gaps in our knowledge are carefully uncovered, which should lead to well-designed randomised controlled trials of sufficient power. Some are undoubtedly underway.

    • © ERS Journals Ltd

    References

    1. ↵
      Kolodziej MA, Jensen L, Rowe B, Sin D. Systematic review of noninvasive positive pressure ventilation in severe stable COPD. Eur Respir J 2007;30:293–306.
      OpenUrlAbstract/FREE Full Text
    2. ↵
      Ambrosino N, Goldstein R. Series on comprehensive management of end-stage COPD. Eur Respir J 2007;30:828–830.
      OpenUrlFREE Full Text
    3. ↵
      Clini E, Sturani C, Rossi A, et al. The Italian multicentre study on noninvasive ventilation in chronic obstructive pulmonary disease patients. Eur Respir J 2002;20:529–538.
      OpenUrlAbstract/FREE Full Text
    4. ↵
      Garrod R, Mikelsons C, Paul EA, Wedzicha JA. Randomized controlled trial of domiciliary noninvasive positive pressure ventilation and physical training in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;162:1335–1341.
      OpenUrlPubMedWeb of Science
    5. ↵
      Díaz O, Bégin P, Torrealba B, Jover E, Lisboa C. Effects of noninvasive ventilation on lung hyperinflation in stable hypercapnic COPD. Eur Respir J 2002;20:1490–1498.
      OpenUrlAbstract/FREE Full Text
    6. ↵
      Díaz O, Bégin P, Andresen M, et al. Physiological and clinical effects of diurnal noninvasive ventilation in hypercapnic COPD. Eur Respir J 2005;26:1016–1023.
      OpenUrlAbstract/FREE Full Text
    7. ↵
      Storre JH, Steurer B, Kabitz HJ, Dreher M, Windisch W. Monitoring of transcutaneous PCO2 during initiation of noninvasive positive pressure ventilation. Chest 2007; 132; 1810–1816
    8. ↵
      Windisch W, Kostić S, Dreher M, Virchow JC Jr, Sorichter S. Outcome of patients with stable COPD receiving controlled noninvasive positive pressure ventilation aimed at a maximal reduction of PaCO2. Chest 2005;128:657–662.
      OpenUrlCrossRefPubMedWeb of Science
    View Abstract
    PreviousNext
    Back to top
    View this article with LENS
    Vol 31 Issue 5 Table of Contents
    European Respiratory Journal: 31 (5)
    • Table of Contents
    • Index by author
    Email

    Thank you for your interest in spreading the word on European Respiratory Society .

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Noninvasive ventilation in severe stable COPD: is it effective, and if so, in what way?
    (Your Name) has sent you a message from European Respiratory Society
    (Your Name) thought you would like to see the European Respiratory Society web site.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Print
    Alerts
    Sign In to Email Alerts with your Email Address
    Citation Tools
    Noninvasive ventilation in severe stable COPD: is it effective, and if so, in what way?
    M. L. Duiverman, F. M. Struik, P. J. Wijkstra
    European Respiratory Journal May 2008, 31 (5) 1136-1137; DOI: 10.1183/09031936.00168207

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero

    Share
    Noninvasive ventilation in severe stable COPD: is it effective, and if so, in what way?
    M. L. Duiverman, F. M. Struik, P. J. Wijkstra
    European Respiratory Journal May 2008, 31 (5) 1136-1137; DOI: 10.1183/09031936.00168207
    del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
    Full Text (PDF)

    Jump To

    • Article
      • References
    • Info & Metrics
    • PDF
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    More in this TOC Section

    • Non-animal models for COVID-19 lung research
    • User-life of ICS/LABA inhaler devices should be considered
    • Peripheral blood eosinophil counts in European and East Asian populations
    Show more Correspondence

    Related Articles

    Navigate

    • Home
    • Current issue
    • Archive

    About the ERJ

    • Journal information
    • Editorial board
    • Reviewers
    • CME
    • Press
    • Permissions and reprints
    • Advertising

    The European Respiratory Society

    • Society home
    • myERS
    • Privacy policy
    • Accessibility

    ERS publications

    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS books online
    • ERS Bookshop

    Help

    • Feedback

    For authors

    • Instructions for authors
    • Submit a manuscript
    • ERS author centre

    For readers

    • Alerts
    • Subjects
    • Podcasts
    • RSS

    Subscriptions

    • Accessing the ERS publications

    Contact us

    European Respiratory Society
    442 Glossop Road
    Sheffield S10 2PX
    United Kingdom
    Tel: +44 114 2672860
    Email: journals@ersnet.org

    ISSN

    Print ISSN:  0903-1936
    Online ISSN: 1399-3003

    Copyright © 2021 by the European Respiratory Society